252 related articles for article (PubMed ID: 3129807)
1. Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects.
MacGregor IR; Roberts EM; Prowse CV; Broomhead AF; Ozolins M; Litka P
Thromb Haemost; 1988 Feb; 59(1):34-9. PubMed ID: 3129807
[TBL] [Abstract][Full Text] [Related]
2. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
[TBL] [Abstract][Full Text] [Related]
3. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
[TBL] [Abstract][Full Text] [Related]
4. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease.
Sultan Y; Loyer F; Venot A
Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP).
Köhler M; Hellstern P; Miyashita C; von Blohn G; Wenzel E
Thromb Haemost; 1986 Feb; 55(1):108-11. PubMed ID: 3085261
[TBL] [Abstract][Full Text] [Related]
6. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
[TBL] [Abstract][Full Text] [Related]
7. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A
Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
[TBL] [Abstract][Full Text] [Related]
8. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
9. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man.
Brommer EJ; Derkx FH; Schalekamp MA; Dooijewaard G; vd Klaauw MM
Thromb Haemost; 1988 Jun; 59(3):404-11. PubMed ID: 3142078
[TBL] [Abstract][Full Text] [Related]
10. [Subcutaneous injection of desmopressin (DDAVP) for increasing factor VIII and von Willebrand factor in plasmapheresis].
Köhler M; Kotitschke R; Braun B; Hellstern P; Mörsdorf S; Pindur G; Heiden M; Wenzel E
Beitr Infusionsther; 1990; 26():136-41. PubMed ID: 1703813
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
[TBL] [Abstract][Full Text] [Related]
12. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs.
Bernat A; Hoffmann P; Dumas A; Serradeil-le Gal C; Raufaste D; Herbert JM
J Pharmacol Exp Ther; 1997 Aug; 282(2):597-602. PubMed ID: 9262320
[TBL] [Abstract][Full Text] [Related]
13. Blood fibrinolysis and the response to desmopressin in glomerulonephritis.
Brommer EJ; Van den Wall Bake AW; Dooijewaard G; van Loon BJ; Emeis JJ; Weening JJ
Thromb Haemost; 1994 Jan; 71(1):19-25. PubMed ID: 8165642
[TBL] [Abstract][Full Text] [Related]
14. Response of factor VIII/von Willebrand factor to intranasal DDAVP in healthy subjects and mild haemophiliacs (with observations in patients with combined deficiency of factors V and VIII).
Garcia VV; Silva IA; Borrasca AL
Thromb Haemost; 1982 Aug; 48(1):91-3. PubMed ID: 6813999
[TBL] [Abstract][Full Text] [Related]
15. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses.
Mannucci PM; Vicente V; Alberca I; Sacchi E; Longo G; Harris AS; Lindquist A
Thromb Haemost; 1987 Dec; 58(4):1037-9. PubMed ID: 3127916
[TBL] [Abstract][Full Text] [Related]
16. Combined haemophilia A and type I von Willebrand's disease: a family study including an evaluation of the effects of DDAVP infusion.
Casonato A; Pontara E; Boscaro M; Dannhauser D; Sartori MT; Girolami A
Haematologia (Budap); 1993; 25(1):57-67. PubMed ID: 8339998
[TBL] [Abstract][Full Text] [Related]
17. DDAVP induces systemic release of urokinase-type plasminogen activator.
Levi M; ten Cate JW; Dooijewaard G; Sturk A; Brommer EJ; Agnelli G
Thromb Haemost; 1989 Sep; 62(2):686-9. PubMed ID: 2510348
[TBL] [Abstract][Full Text] [Related]
18. Additive effect of dDAVP and standard heparin in increasing plasma t-PA.
Agnelli G; Levi M; Cosmi B; ten Cate JW; Nenci GG
Thromb Haemost; 1989 Jun; 61(3):507-10. PubMed ID: 2508260
[TBL] [Abstract][Full Text] [Related]
19. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
[TBL] [Abstract][Full Text] [Related]
20. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
Köhler M; Miyashita C
Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
